D2 dopamine receptor-expressing medium spiny neurons (D2-MSNs) are GABAergic projection neurons that form the indirect pathway of the basal ganglia. They represent approximately half of all striatal neurons and are distinguished from D1-MSNs by their expression of dopamine D2 receptors, adenosine A2A receptors, and the neuropeptide enkephalin. D2-MSNs receive convergent input from the cerebral cortex, thalamus, and dopamine neurons of the substantia nigra pars compacta, and project to the globus pallidus externus (GPe) to modulate motor action selection.
The defining feature of D2-MSNs is their inhibitory response to dopamine: dopamine binding to D2 receptors suppresses adenylyl cyclase activity, reduces cAMP production, and decreases the excitability and synaptic strength of these neurons. This contrasts with D1-MSNs, which are excited by dopamine through D1 receptors. The D1/D2 balance determines the net output of the basal ganglia motor circuit.
| Receptor | Gene | Signaling | Function in D2-MSNs |
|---|---|---|---|
| D2 dopamine receptor | DRD2 | Gi/o-coupled, inhibits AC | Suppresses cAMP, reduces excitability |
| A2A adenosine receptor | ADORA2A | Gs-coupled, activates AC | Modulates excitability, target of istradefylline |
| Enkephalin | PENK | Neuropeptide co-transmitter | Inhibits mu-opioid receptor expressing targets |
| RGS9 complex | RGS9, RGS9BP | GAP for Gi/o proteins | Regulates D2 receptor signaling, implicated in dyskinesia |
| PDE10A | PDE10A | cAMP/cGMP hydrolysis | Highly enriched in striatum, therapeutic target |
DARPP-32 (dopamine- and cAMP-regulated neuronal phosphoprotein, 32 kDa) is the key integrator of D1 and D2 receptor signaling. When dopamine binds D2 receptors (Gi-coupled), it reduces cAMP, dephosphorylating DARPP-32 at Thr34 through PP1 activation. This converts DARPP-32 from a PKA inhibitor to a PP1 activator, creating a brake on signaling that reshapes ion channel conductances governing neuronal excitability and synaptic gain.
D2-MSNs constitute the indirect pathway:
The indirect pathway operates as a "brake" on motor behavior:
This brake is normally released when dopamine acts on D2 receptors to inhibit D2-MSNs, allowing movement to proceed.
In Parkinson's disease, loss of dopaminergic input to the striatum has particularly severe effects on D2-MSNs:
In Huntington's disease, D2-MSNs are preferentially vulnerable to early degeneration, contributing to the chorea and involuntary movements characteristic of the disease:
In corticobasal degeneration, D2-MSN dysfunction contributes to the rigidity, akinesia, and limb dystonia seen in this disorder. The tau pathology underlying CBD disrupts striatal circuitry, including D2-MSN function, contributing to both motor and cognitive symptoms.
D2-MSN signaling cascades in the context of PD:
| Target | Drug/Approach | Status | Rationale |
|---|---|---|---|
| A2A receptor | Istradefylline | Approved (PD) | Block A2A overactivity, reduce indirect pathway overinhibition |
| A2A receptor | Preladenant, Tozadenant | Withdrawn/Phase III | Next-gen A2A antagonists |
| PDE10A | MP-10, TAK-063 | Preclinical/Phase I | Increase cAMP/cGMP signaling in MSNs |
| D2 receptor | Rotigotine | Approved (PD) | Direct D2 agonism, overcomes dopamine loss |
| RGS9 | Antisense oligonucleotides | Preclinical | Reduce dyskinesia by restoring D2 signaling |
| mGluR5 | ABT-354 | Preclinical | Modulate corticostriatal transmission |
| Partner | Interaction | Role |
|---|---|---|
| D1-MSNs | Parallel pathway | Direct vs indirect pathway balance |
| Substantia nigra DA neurons | Dopaminergic input | Motor facilitation |
| Globus pallidus externus | GABAergic output | Movement suppression control |
| Cortex | Glutamatergic input | Action initiation signals |
| Adenosine system | A2A-D2 heterodimer | Therapeutic targeting |